Vaxart (OTCMKTS:VXRT) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

Vaxart, Inc. (OTCMKTS:VXRT) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.59 and traded as low as $0.55. Vaxart shares last traded at $0.5686, with a volume of 275,711 shares trading hands.

Vaxart Stock Performance

The firm has a market capitalization of $135.96 million, a price-to-earnings ratio of 3.73 and a beta of 1.10. The stock’s fifty day moving average is $0.67 and its two-hundred day moving average is $0.59.

Vaxart (OTCMKTS:VXRT) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02. The company had revenue of $39.23 million during the quarter, compared to analyst estimates of $50.50 million. Vaxart had a net margin of 14.51% and a return on equity of 61.43%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. grew its holdings in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 34,075 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Vaxart in the 2nd quarter worth about $794,000. Creative Planning bought a new position in shares of Vaxart in the 2nd quarter worth about $33,000. Goldman Sachs Group Inc. bought a new position in shares of Vaxart in the 1st quarter worth about $31,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after buying an additional 478,111 shares during the last quarter. 18.05% of the stock is owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.